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Abstract
CD4+CD8+ double-positive thymocytes differentiate into CD4+ and CD8+ single-positive T cells
during thymic positive selection. This process requires the interaction between the TCR and self
MHC molecules. In this context we have analyzed the expression of CD45, an abundant
transmembrane protein tyrosine phosphatase, and describe here its differential surface expression
during T cell maturation. Using four-color FACS analysis of thymocytes from normal as well as
TCR-transgenic mice we demonstrate that CD45 is up-regulated only during positive selection
concomitantly with the TCR-CD3 complex and the transient early activation marker CD69, but that
this up-regulation precedes heat stable antigen down-regulation. The tight linkage of the up-
regulation of the TCR-CD3 complex and CD45 may be required because the CD45 tyrosine
phosphatase plays a role in modulating signal transduction by the TCR-CD3 complex during
positive selection. In addition, our findings argue for a regulation mechanism that adapts the CD45
levels to increasing antigen receptor levels on mature T cells and B cells.
Introduction
CD45 is a transmembrane protein tyrosine phosphatase
abundantly present on the cell surface of all nucleated
hematopoietic cells. This protein exists in several isoforms
due to alternative splicing of four of its exons (for reviews see
1,2). Studies with CD45" mutant cell lines that were antigen
receptor "signaling deficient showed that expression of CD45
is a prerequisite for transmembrane signal transduction upon
triggering of the TCR (3,4) as well as the B cell antigen receptor
(5). It was further demonstrated that CD45 dephosphorylates
specifically negative regulatory tyrosine residues of src family
protein tyrosine kinases, an event that results in increased
kinase activity in T cells (6-9) and B cells (5,10,11). The
disruption of the CD45 gene underlined clearly the essential
role of this phosphatase in T lymphocyte development and B
cell function, since it resulted in a drastic reduction of mature
single-positive thymocyte numbers and mature B lymphocytes
with signaling-deficient antigen receptors (12).
Protein phosphorylation is an important mechanism of trans-
ducing signals in eukaryotic cells. It has been proposed that
a resting cell is maintained below a threshold for signaling
through a balance between opposing dephosphorylation and
phosphorylation reactions (13). In fact, chemical inactivation
of phosphatases in Jurkat cells leads to IL-2 production
without TCR triggering (14), which indicates that the cell has
to regulate both opposing activities tightly to keep them
in balance.
Little is yet known about the regulation of CD45-phosphat-
ase activity. It has been suggested that the different isoforms
of CD45 could interact with different ligands and become
thereby differentially activated (for review see 2). When mouse
thymocytes were previously investigated for expression of
certain isoforms that might correlate to positive or negative
selection events, not all analyzed thymocytes (only 1-3%)
expressed specific isoforms (15).
Therefore, in the present study we used three different
CD45 pan-isoform-specific reagents together with CD4, CD8
and CD3, heat stable antigen (HSA) or CD69 as thymocyte
markers as well as IgM, IgD, CD19 or B220 as B lymphocyte
markers and extensively analyzed CD45 expression (regard-
less of isoforms) in various thymocyte subsets as well as
during B cell development.
In clear contrast to earlier reports (16), we demonstrate in
this study that there is an extremely tight correlation between
CD45 expression levels and positive selection events in the
thymus. More than 90% of all positively selected thymocytes
showed a CD45hiQh phenotype, whereas basically all non-
selected thymocytes stained CD45|OW. Similarly, we could
detect a drastic CD45 up-regulation during B cell development
that paralleled B cell antigen receptor up-regulation and B
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Fig. 1. Four-color FACS analysis of B6.SJL (Ly-5a) thymocytes: CD4 and CD8 expression was analyzed with a gate set on forward versus side
scatter parameters to exclude dead cells and debris. Subsequently, nine gates, corresponding to different developmental stages between
CD4+CD8+ DP and CD4+ SP and CD8+ SP thymocytes, were introduced. The lower three panels show for each of these nine gates the
analysis with the following pairs of mAb: lower left, center and right panels show CD45 (clone 104.2.1) versus CD3, CD69 or HSA respectively.
In each panel, gate 1 (CD4+CD8+ DP cells) corresponds to the top middle position, while gates 2-5 descend to the left (towards CD4+ SP
cells) and gates 6-9 descend to the right (towards CD8+ SP cells). A total of 3X105 cells were analyzed. All cells within the forward versus
side scatter parameters are displayed in the top panel, whereas 2000 cells of the gated subpopulations are shown in the small panels below.
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Table 1. CD45 and TCR up-regulation during thymocyte maturation
CD45
CD3
CD4
Total
588
10.8
109
Gate 1
CD4+CD8+
541
5.7
102
Gate 2
570
7.4
111
Gate 3
744
24.0
90
Gate 4
931
52.1
110
Gate 5
990
62.15
115
Gate 6
CD4+CD8-
1009
63.5
126
Data are derived from the same analysis as shown in Fig. 1. Similar to Fig. 1, six gates were set to cover the developmental transition
between immature CD4+CD8+ and mature CD4+CD8~ T cells. The mean relative fluorescence intensity of CD45, CD3 and CD4 of the various
subpopulations is shown.
cell maturation. We discuss the implications of these findings
with respect to TCR and B cell receptor expression levels
during lymphocyte development.
Methods
Mice
B6.SJL (Ly-5a) and C56BL/6 mice were purchased from
Jackson Laboratories (Bar Harbor, ME) or IFFA Credo
(Orleans, France) respectively. TCR transgenic mice, with a
hemagglutinin-specific, l-Ed-restricted TCR, were as
described before and crossed to a recombination activating
gene negative (RAG-2^-) background (17). Since RAG-2"'"
mice were a mixture of Ly-5a and Ly-5b mice, we selected
for these markers to obtain Ly-5a or Ly-5b homozygotes.
Phenotyping was done by FACS staining of peripheral blood
lymphocytes with mAb specific for TCR Vp8, TCR clonotype,
Ly-5 allele and Dd or Kb. Mice were bred in the animal colony
of the Basel Institute for Immunology and were analyzed at
6-10 weeks of age.
mAb and FACS analysis
Hybridoma supernatants containing mAb were purified by
Protein G (Pharmacia, San Diego, CA)-affinity chromato-
graphy. mAb were labeled using biotin- or fluorescein-
succinimidyl-ester (FLUOS) according to the manufacturer's
instructions. The following mAb were used: T19.191 (anti-
Dd) (17), AF6-88.5.3 (anti-Kb) (18), M1/69 (anti-HSA) (19),
KT-3 (anti-CD3) (20), F23.1 (anti-TCR Vp8) (21), A20-1.7 (anti-
Ly-5b) (22), 104.2.1 (anti-Ly-5a) (22) and 6.5 (anti-clono-
typic TCR) (23). Anti-CD4-phycoerythrin (Becton Dickinson,
Plymouth, UK), anti-CD8-Red613 (Gibco/lmmunoselect/BRL,
Grand Island, NY), anti-lgD (clone 217-170; PharMingen, San
Diego, CA), anti-IgM (clone AF6-78; PharMingen), RA3-6B2
(anti-CD45, B220 isoform; PharMingen) and anti-CD45-FITC
(clone 30F11.1, specific for all CD45 isoforms; PharMingen)
conjugates were obtained commercially. With these and the
second step reagent streptavidin-allophycocyanin (APC;
Molecular Probes, Eugene, OR) four color flow-cytometry was
performed on a FACStar"1" (Becton Dickinson) instrument
equipped appropriately.
Single cell preparation, staining and FACS analysis were
done according to standard procedures.
Results
In order to investigate the expression of CD45 on thymocytes
of B6.SJL mice that were homozygous for one of the CD45
alleles (Ly-5a), we performed four-color flow cytometric ana-
lysis with mAb specific for CD4, CD8, CD45 and a fourth
marker (CD3, CD69 or HSA respectively) (Fig. 1). We first
analyzed the thymocytes according to their CD4 and CD8
expression and gated them in distinct developmental stages
between double-positive (DP) and single-positive (SP) thymo-
cytes (see Fig. 1, gates 1-9). We further analyzed the cells
in gates 1-9 according to their expression of CD45 versus
either CD3, CD69 or HSA. Figure 1 shows that the expression
levels of CD45 increase during maturation of thymocytes (Fig.
1, lower part, with the DP fraction of gate 1 on the top of the
two columns and the maturing CD4+ SP cells shown in the
dot-plots descending to the left, the CD8+ SP cells to the
right). In the lower left panel of Fig. 1, CD45 expression is
correlated with TCR-CD3 complex expression as measured
by a mAb specific for CD3e. While all DP thymocytes are dull
for CD3 and positive for CD45, >90% of the most mature
CD4+ SP cells are expressing higher levels of CD3 and CD45.
The same shift can be observed for CD8+ SP thymocytes
with the remaining CD3dullCD45low cells being immature CD8+
SP (24,25).
When we compared CD69 and CD45 (Fig. 1) we observed
the expected transient up-regulation of CD69 (26) by thymo-
cytes on their way to mature CD4+ SP or CD8+ SP cells. This
transient up-regulation of CD69 takes place at the same stage
as CD45 up-regulation. With further maturation CD69 is down-
regulated again, while CD45 expression levels remain high
(Fig. 1, gates 5 and 9). Immature CD8+ SP thymocytes remain
CD45 low (see lower right dot-plot corresponding to
gate 9).
We then analyzed the expression of CD45 in the context of
HSA. As described previously, immature thymocytes express
high levels of HSA and lose this marker on their way to mature
SP cells (27). According to Fig. 1 (right lower panel) practically
all of the more mature thymocytes became CD45h'9h before
they started to lose HSA expression.
Quantitative analysis of three surface markers shows that
CD4 levels do not change, CD3 is up-regulated -12 times
and CD45 levels are increased 2-fold during thymocyte
maturation as shown in Table 1.
In order to see whether this event is dependent on positive
selection, we repeated the experiments in RAG-2~'~ TCR-
transgenic mice that can or cannot positively select immature
thymocytes. As previously described (17), in the I-Ed+ TCR-
transgenic RAG-2"'" mice, positive selection leads to the
presence of CD4+ SP and CD8+ SP mature thymocytes (Fig.
2) while in the corresponding i-E6' mice such cells cannot
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be detected (Fig. 2). We gated on CD4+CD8+ DP, CD4+ SP
or CD8+ SP thymocytes (gates 1, 2 and 3), and analyzed
them for CD45 versus CD3, CD69 and HSA. In case of
I-Ed+ TCR-transgenic RAG-2"'"" mice we observed the same
correlation between these markers as described above: CD45
is up-regulated during positive selection on thymocytes (Fig.
2). In contrast, thymocytes from I-Ed"TCR-transgenic RAG-2^"
mice that cannot positively select with this TCR remain
CD45l0W (Fig. 2). Thus CD45 up-regulation is dependent on
positive selection events.
To test whether CD45 up-regulation is allele-specific we
compared I-Ed+ and I-Ed" TCR-transgenic RAG-2~'~ mice that
were homozygous for the CD45 allele Ly-5b. As shown in Fig.
3, we obtained similar results as in Ly-5a mice. Apparently
CD45 up-regulation upon positive selection is a general
phenomenon, not restricted to a particular allele.
While the majority of thymocytes and activated T cells
express different low mol. wt isoforms of CD45, B220, a high
molecular isoform of CD45, has been routinely used as a
marker for all B lineage cells (1,28). We were interested if the
observed CD45 up-regulation during T cell maturation could
similarly be detected with a pan-isoform CD45 specific mAb
on developing B cells in the bone marrow. To this end we
analyzed bone marrow cells as shown in Fig. 4. To concentrate
on B lineage cells, we first gated on B220+ cells (data not
shown). According to their surface IgM and IgD expression
we divided these into four stages corresponding to gates
1-4: IgM/lgD double negative (gate 1), lgMl0W SP (gate 2),
igMhigh S P a n d |gMhigh/|gD'°w DP (gate3), and IgM/lgD DP
(gate 4), reflecting the normal B cell developmental pathway.
When these four populations were analyzed for CD45 expres-
sion levels, we found an up-regulation of CD45 (see histo-
grams in Fig. 4) tightly linked to surface Ig up-regulation and
B cell maturation.
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Fig. 3. Three-color FACS analysis of I-E+ and I-E" RAG-2~'~ Ly-5b TCR-transgenic thymocytes. Analysis was performed as described for Fig.
2, but with a pan-specific CD45 mAb (clone 30F11.1).
Fig. 2. Four-color FACS analysis of I-Ed+ and I-Ed~ RAG-2^" Ly-5a TCR-transgenic thymocytes. Analysis and data display was performed as
described for Fig. 1. CD4+CD8+ DP, CD4+ SP or CD8+ SP thymocytes were analyzed using gates 1, 2 and 3 as shown. In each panel, CD4+
SP, CD4+CD8+ DP and CD8+ SP cells correspond to the upper left, upper right or lower right dot-plot respectively.
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Fig. 4. Four-color FACS analysis of bone marrow. Bone marrow cells were isolated from C57BL/6 mice. Dead cells and debris was excluded
with a gate set on forward versus side scatter parameters. For further analysis, only B220+ cells were included. These were divided into four
populations based on IgM and IgD expression. For each of these four populations, the histograms show the expression of CD45 (clone 30F11.1).
Discussion
Earlier studies have shown that it is difficult to define rules for
the regulation of CD45 isoform expression on thymocytes,
since only minimal populations (1-3%) express specific iso-
forms (CD45RA and CD45RBh'9h) that occur during positive
or negative selection in the thymus (15). Since a much higher
percentage of thymocytes are positively selected in normal
and TCR-transgenic mice but do not express or up-regulate
certain CD45 isoforms, we investigated the overall expression
levels of CD45 on thymocytes with pan-CD45 antibodies to
see if isoform-independent regulation might occur. Using four-
color flow cytometry we analyzed thymocytes from normal
and TCR-transgenic mice and compared CD45 expression
levels with other more commonly used thymocyte markers
like CD3, CD69 and HSA. As measured with three different
mAb specific for all isoforms of CD45, we describe here
that CD45 expression levels are lower on CD4+CD8+ DP
thymocytes, but increase when these cells mature to the
CD4+ SP or CD8+ SP stage. The CD45 up-regulation occurs
simultaneously with an increase of TCR-CD3 levels and one
might argue that the CD45 phosphatase levels are increased
because of an ongoing increase of TCR-CD3 levels in order to
regulate signals received during thymocyte positive selection.
Nearly all (>90%) thymocytes followed this rule.
Interestingly, during B cell development, the CD45 isoform
B220 shows a similar shift in surface expression (29). However,
as yet undetected was the general, isoform-independent up-
regulation of CD45 expression when B cells start to express
Ig, as shown in this study.
These findings indicate that the total CD45 levels (regard-
less of its isoforms) may be important in developing lympho-
cytes to regulate signal transduction activity during
lymphocyte maturation.
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APC allophycocyanin
DP double positive
HSA heat shock antigen
SP single positive
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